Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer

BACKGROUND: Despite the success of tamoxifen since its introduction, about one-third of patients with estrogen (ER) and/or progesterone receptor (PgR) - positive breast cancer (BC) do not benefit from therapy. Here, we aim to identify molecular mechanisms and protein biomarkers involved in tamoxifen...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansson, Henrik J, Sanchez, Betzabe C, Forshed, Jenny, Stål, Olle, Fohlin, Helena, Lewensohn, Rolf, Hall, Per, Bergh, Jonas, Lehtiö, Janne, Linderholm, Barbro K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389343/
https://www.ncbi.nlm.nih.gov/pubmed/25878567
http://dx.doi.org/10.1186/s12014-015-9080-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389343/
https://www.ncbi.nlm.nih.gov/pubmed/25878567
http://dx.doi.org/10.1186/s12014-015-9080-y

Ejemplares similares